Home › Compare › MVRBF vs GBDC

MVRBF vs GBDC: Dividend Comparison 2026

MVRBF yields 243.90% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVRBF wins by $373.77M in total portfolio value
10 years
MVRBF
MVRBF
● Live price
243.90%
Share price
$0.82
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.62M
Annual income
$218,439,906.42
Full MVRBF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — MVRBF vs GBDC

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVRBFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVRBF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MVRBF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF
Annual income on $10K today (after 15% tax)
$20,731.71/yr
After 10yr DRIP, annual income (after tax)
$185,673,920.46/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, MVRBF beats the other by $171,690,796.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + GBDC for your $10,000?

MVRBF: 50%GBDC: 50%
100% GBDC50/50100% MVRBF
Portfolio after 10yr
$207.73M
Annual income
$117,445,320.13/yr
Blended yield
56.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

MVRBF
No analyst data
Altman Z
1.7
Piotroski
0/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys
0
GBDC buys
0
No recent congressional trades found for MVRBF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVRBFGBDC
Forward yield243.90% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$394.62M ✓$20.85M
Annual income after 10y$218,439,906.42 ✓$16,450,733.83
Total dividends collected$375.65M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MVRBF vs GBDC ($10,000, DRIP)

YearMVRBF PortfolioMVRBF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$35,090$24,390.24$12,492$1,791.70+$22.6K → MVRBF
2$117,533$79,986.88$16,527$3,160.58+$101.0K → MVRBF
3$376,147$250,386.00$23,588$5,904.90+$352.6K → MVRBF
4$1,151,374$748,897.11$37,141$11,901.65+$1.11M → MVRBF
5$3,374,355$2,142,384.97$66,205$26,463.38+$3.31M → MVRBF
6$9,478,533$5,867,972.46$137,452$66,612.65+$9.34M → MVRBF
7$25,546,778$15,404,747.63$342,372$195,298.53+$25.20M → MVRBF
8$66,138,099$38,803,046.68$1,053,292$686,954.33+$65.08M → MVRBF
9$164,653,072$93,885,306.32$4,111,439$2,984,416.95+$160.54M → MVRBF
10$394,618,693$218,439,906.42$20,849,974$16,450,733.83+$373.77M → MVRBF

MVRBF vs GBDC: Complete Analysis 2026

MVRBF — Stock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this MVRBF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHDMVRBF vs JEPIMVRBF vs OMVRBF vs KOMVRBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.